Short interest in Raptor Pharmaceuticals (RPTP) increased by 6% over the last two months, in tandem with the stock's rise to $6.28, which has since pressured shares into a downward move. But the move back to the $4 range has created an opportunity for investors to take advantage of an upcoming value-driving event: the April 30 PDUFA for lead candidate Procysbi (RP-103) (Read more in PropThink's original report, which returned 19% in the two weeks following publication).
Procysbi, or delayed release cysteamine bitartrate, is an oral therapy for nephropathic cystinosis and incrementally improves on the only other existing therapy, Cystagon (cysteamine bitartrate), marketed by Mylan (MYL). An ultra-rare disease, nephropathic cystinosis affects just 2,000 patients globally, but Procysbi's improved dosing, frequency, and fewer side effects compared to Cystagon suggest that Procysbi could capture the lion's share of this small patient population. Procysbi's approval is a near-certainty given the widespread acceptance of the immediate release formulation and considering that it reaches an underserved patient population.
As many have pointed out, Procysbi will likely be priced much higher than the $10K annual price tag for Cystagon, a possible deterrent to reimbursement but a facet that management feels confident it can address appropriately. A price tag similar to other orphan drugs, from $100K-$300K annually, would imply that RPTP is considerably undervalued, while our most conservative pricing model ($50K annually) indicates that RPTP is already at or near fair value. Analysts have been optimistic about the drug's prospects, and price targets average $9.86. We're cautiously optimistic about Procysbi's ability to drive meaningful value for Raptor Pharmaceuticals. Overall, long-term prospects for RPTP hinge predominantly on Procysbi's price and payer acceptance, and we're playing RPTP primarily as a short-term trade for now; the stock is already in oversold territory and near key support levels, suggesting a bounce may be imminent.
Cautiously optimistic about Procysbi's benefits, costs, and reimbursement. In patients with nephropathic cystinosis, cystinosin, the lysosomal transporter that carries the amino acid cystine out of cells, is defective, and leads to the intracellular accumulation of cystine. Cystine accumulation ultimately forms minute crystals in organ tissue, causing damage primarily in the kidneys and eyes. Crystal build-up in the kidney can worsen to the point of kidney failure and patient death, and since the disease is often diagnosed in infancy, patients sometimes require kidney transplant by the time they reach adolescence. Cystagon (cysteamine bitartrate) has been used to treat nephrotic cystinosis for years and is an efficacious, albeit burdensome, long-term treatment. Patients take Cystagon orally four times daily, including one dose in the middle of the night, and treatment relies on a heavy pill burden. Patients on Cystagon often require proton pump inhibitors (PPI) as well to mitigate cysteamine-related GI issues, and given that most patients are in their adolescent or teen years, compliance is a clear issue.
In a 43-patient Phase III trial, Procysbi, a long-lasting formulation of cysteamine bitartrate, demonstrated non-inferiority to Cystagon when taken at 12 hour intervals as opposed to Cystagon's four times daily dosing and required an average of 82% of Cystagon's solid-state dosage. 40 of the 43 patients in the Phase III trial elected to enroll in a 24-month extension study and demonstrated a reduction in concomitant use of anti-acid medications by nearly half, with only 22% of patients taking PPI's or histamine 2 blockers during the extension, compared to 42% upon initially entering the study. Thus, the benefits of Procysbi include less frequent dosing, lower pill burden, and improved tolerability; 88% of providers have indicated that they'll switch patients from Cystagon to Procysbi upon availability.
The question is how much can Raptor charge for these incremental benefits? The company has yet to issue an estimate, but with just 2,000 patients globally (including 500 in the U.S. and 800 in Europe), Procysbi's price will be highly determinant of value to the company and its shareholders. Analysts have cited orphan drug pricing scenarios in the $200-$300K range, an expense that we believe may be tough for payers to swallow despite Procysbi's orphan drug status and rare occurrence. With an existing treatment (Cystagon) that's equally effective, marginally less tolerable, dosed twice as frequently, but available for $10K annually, the orphan drug pricing methodology is less applicable to Procysbi, and an extraordinary price will be met with payer resistance. Raptor COO Julie Ann Smith indicated that payers who Raptor has approached plan to handle the treatment the same way they do other ultra orphan drugs: on a case-by-case basis. The company is already making a concerted effort to understand the market in advance of commercialization; mapping Cystagon prescribers, patients and advocacy groups, readying a sales force, and ramping up a patient assistance program.
We see value in Procysbi under a few plausible scenarios, all reliant on widespread reimbursement. Assuming Procysbi actually captures 88% of the estimated 500-patient North American market, 50% of the remaining 1500 patients worldwide, and is priced at $100K annually, Raptor could see global revenues of $119M yearly. If sell-side analysts prove correct, and Procysbi is priced around $200K, our revenue approximation doubles to $238M. Conversely, if Procysbi prices at a more conservative $50K annually (five-fold that of Cystagon), Raptor sees $59.5M. We apply a 4x sales multiple to reach a back-of-the-envelope valuation for RPTP, and in all but the most conservative of our estimates, projections indicate that Raptor's $250M market capitalization is decidedly low.
For now, we're focused on the short-term trade and are well-aware of the risks around Procysbi pricing, reimbursement, and commercial viability in nephropathic cystinosis. Raptor's balance sheet is sound since securing a $50M loan in December. Taking the loan into consideration, existing capital will take RPTP through approval and may even be sufficient for Procysbi's launch later this year, as the sales force required to market the orphan drug will be minimal. Tuesday will be a key test of support at $4.76, last Friday's closing price. RPTP's 14-day RSI of 17 indicates that the stock is considerably oversold and may be prepared for a bounce, but if this multi-week down-trend continues, we'll be looking for a reversal at the $4.35 support level. Following confirmation, we anticipate a run into the April 30 FDA decision.
Additional disclosure: PropThink is a team of editors, analysts, and writers. This article was written by Jake King. We did not receive compensation for this article, and we have no business relationship with any company whose stock is mentioned in this article. Use of PropThink’s research is at your own risk. You should do your own research and due diligence before making any investment decision with respect to securities covered herein.You should assume that as of the publication date of any report or letter, PropThink, LLC and persons or entities with whom it has relation ships (collectively referred to as "PropThink") has a position in all stocks (and/or options of the stock) covered herein that is consistent with the position set forth in our research report. Following publication of any report or letter, PropThink intends to continue transacting in the securities covered herein, and we may be long, short, or neutral at any time hereafter regardless of our initial recommendation. To the best of our knowledge and belief, all information contained herein is accurate and reliable, and has been obtained from public sources we believe to be accurate and reliable, and not from company insiders or persons who have a relationship with company insiders. Our full disclaimer is available at www.propthink.com/disclaimer.